Skip Navigation
Menu
Letters |15 October 2019

Prevalence of Aspirin Use for Primary Prevention of Cardiovascular Disease in the United States: Results From the 2017 National Health Interview Survey

Colin W. O'Brien, MD; Stephen P. Juraschek, MD, PhD; Christina C. Wee, MD, MPH

Article, Author, and Disclosure Information
Author, Article, and Disclosure Information
This article was published at Annals.org on 23 July 2019.
  • Harvard Medical School, Boston, Massachusetts (C.W.O.)
    Beth Israel Deaconess Medical Center and Harvard Medical School, Boston, Massachusetts (S.P.J., C.C.W.)

    Note: The institutional review board at Beth Israel Deaconess Medical Center deemed this study not to be human subjects research.

    Acknowledgment: The authors thank Aaron Fleishman, MPH, for checking the statistical programs and outputs and the participants of NHIS for their important contributions.

    Grant Support: Dr. Juraschek is supported by grant K23HL135273 from the National Heart, Lung, and Blood Institute of the National Institutes of Health.

    Disclosures: Disclosures can be viewed at www.acponline.org/authors/icmje/ConflictOfInterestForms.do?msNum=M19-0953.

    Reproducible Research Statement: Study protocol and data set: Publicly available at www.cdc.gov/nchs/nhis/index.htm. Statistical code: Available from Dr. Wee (e-mail, cwee@bidmc.harvard.edu).

×
FULL TEXT
Background: Physicians and medical professional societies have widely supported use of aspirin for primary prevention of cardiovascular disease (CVD) in persons who are at increased risk (1) (Table 1). Three randomized controlled trials published in 2018—ASCEND (A Study of Cardiovascular Events in Diabetes), ARRIVE (Aspirin to Reduce Risk of Initial Vascular Events), and ASPREE (Aspirin in Reducing Events in the Elderly)—sought to evaluate the benefits and risks of aspirin use for primary prevention of CVD in adults with diabetes, average-risk adults, and older adults, respectively (2–4). Collectively, these studies showed few benefits and consistent...
FULL TEXT
PDF
Not Available
Citations
Citation

O'Brien CW, Juraschek SP, Wee CC. Prevalence of Aspirin Use for Primary Prevention of Cardiovascular Disease in the United States: Results From the 2017 National Health Interview Survey. Ann Intern Med. 2019;171:596–598. [Epub ahead of print 23 July 2019]. doi: https://doi.org/10.7326/M19-0953

Download citation file:

© 2019

×
Permissions

Published: Ann Intern Med. 2019;171(8):596-598.

DOI: 10.7326/M19-0953

Published at www.annals.org on 23 July 2019

©
2019 American College of Physicians
0 Citations

Related Articles
Annals for Educators - 19 March 2019
Annals of Internal Medicine; 170 (6): ED6
Aspirin Use for the Primary Prevention of Cardiovascular Disease and Colorectal Cancer: Recommendations From the U.S. Preventive Services Task Force
Annals of Internal Medicine; 164 (12): I-22
Review: Current evidence shows no overall benefit of aspirin for primary prevention of cardiovascular disease in diabetes
Annals of Internal Medicine; 152 (8): JC4-10
The Cost-Effectiveness of Aspirin, Statins, or Both Drugs in the Primary Prevention of Heart Disease
Annals of Internal Medicine; 144 (5): I-29
View MoreView Less

Journal Club
Review: Current evidence shows no overall benefit of aspirin for primary prevention of cardiovascular disease in diabetes
Annals of Internal Medicine; 152 (8): JC4-10
Review: In newer CVD primary prevention trials, aspirin vs no aspirin does not reduce MI and increases major bleeding
Annals of Internal Medicine; 171 (10): JC55
Review: After stroke or TIA, adding clopidogrel to aspirin for ≤ 1 month reduces recurrence and MACE
Annals of Internal Medicine; 171 (4): JC14
Aspirin before fecal immunochemical testing did not increase sensitivity for detecting advanced colorectal neoplasms
Annals of Internal Medicine; 171 (4): JC20
View MoreView Less

Related Topics
Cardiology
Coronary Risk Factors
Prevention/Screening

Cardiology, Coronary Risk Factors, Prevention/Screening.

PubMed Articles
New approaches for the assessment of platelet activation status in thrombus under flow condition using confocal microscopy.
Naunyn Schmiedebergs Arch Pharmacol 2019.
Risk of Free Flap Failure in Head and Neck Reconstruction: Analysis of 21,548 Cases From A Nationwide Database.
Ann Plast Surg 2020;84(1S Suppl 1):S3-S6.
View More

Results provided by: PubMed

CONTINUE WITH LIMITED ACCESS
Annals of Internal Medicine
To receive access to the full text of freely available articles, alerts, and more. You will be directed to acponline.org to complete your registration.
×
acp link acp
silverchair link silverchair

Copyright © 2019 American College of Physicians. All Rights Reserved.

Print ISSN: 0003-4819 | Online ISSN: 1539-3704

Privacy Policy

|

Conditions of Use

This site uses cookies. By continuing to use our website, you are agreeing to our privacy policy. | Accept
×

You need a subscription to this content to use this feature.

×
PDF Downloads Require Access to the Full Article.
Annals of Internal Medicine
To receive access to the full text of freely available articles, alerts, and more. You will be directed to acponline.org to complete your registration.
×
Access to this Free Content Requires Users to be Registered and Logged In. Please Choose One of the Following Options
Annals of Internal Medicine
To receive access to the full text of freely available articles, alerts, and more. You will be directed to acponline.org to complete your registration.
×